Aba - Invest In Austria

Alzheimer's Vaccine: AFFiRiS AG Announces Data on Lead Product AD02: Information on Efficacy

Older News

VIENNA, Austria, March 11, 2011 - Today, AFFiRiS AG presented the evaluation of secondary endpoints of a clinical phase I study of their Alzheimer's vaccine AD02.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy